PubMatic, Eventbrite, Five9 And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Portfolio Pulse from Avi Kapoor
Several major stocks, including PubMatic, Eventbrite, Five9, Zevra Therapeutics, Array Technologies, e.l.f. Beauty, and Lumen Technologies, are experiencing significant declines in pre-market trading due to various factors such as worse-than-expected earnings, revenue guidance cuts, and public offerings.
August 09, 2024 | 10:44 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Array Technologies shares fell 11.3% in pre-market trading after the company cut its FY24 guidance.
The reduction in future guidance led to a decline in investor confidence, causing the stock to drop.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Eventbrite shares declined 17.1% in pre-market trading after reporting worse-than-expected Q2 revenue and issuing weak FY24 revenue guidance.
The combination of a revenue miss and weak future guidance led to a significant drop in the stock price.
CONFIDENCE 100
IMPORTANCE 85
RELEVANCE 100
NEGATIVE IMPACT
e.l.f. Beauty shares declined 8.4% in pre-market trading following quarterly results.
The market's reaction to the quarterly results led to a decline in the stock price.
CONFIDENCE 85
IMPORTANCE 65
RELEVANCE 100
NEGATIVE IMPACT
Five9 shares dipped 16.4% in pre-market trading after posting second-quarter results.
The market reacted negatively to the company's Q2 results, leading to a significant drop in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
NEGATIVE IMPACT
Lumen Technologies shares fell 4.5% in pre-market trading after a 19% decline on Thursday.
The continued decline in stock price suggests ongoing negative sentiment among investors.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 100
NEGATIVE IMPACT
PubMatic shares fell 26.4% in pre-market trading after reporting worse-than-expected Q2 revenue, despite beating earnings estimates.
The significant revenue miss overshadowed the earnings beat, leading to a sharp decline in the stock price.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
Zevra Therapeutics shares fell 16.6% in pre-market trading after pricing its $60 million public offering at $6.50 per share.
The public offering at a lower price than the current market price led to a decline in the stock.
CONFIDENCE 100
IMPORTANCE 80
RELEVANCE 100